drug adverse effects of gliptins
Jump to navigation
Jump to search
Adverse effects
- nausea[3]
- increased risk of pancreatitis[1][5][7][10] & pancreatic cancer[10]
- anaphylaxis
- severe arthralgias[2]
- increased risk for infections[3]
- increased risk for hospitalization due to heart failure (3.4% vs 3.0%), NNH = 250[4]
- increased risk of inflammatory bowel disease[8]
- increased risk for cholangiocarcinoma[9]
- no increased risk of mortality[6]
- rarely causes hypoglycemia[11]
* unfavorable adverse effect profile including anaphylaxis & pancreatitis[7]
More general terms
References
- ↑ 1.0 1.1 Singh S et al Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus. A Population-Based Matched Case-Control Study. JAMA Intern Med. 2013;():1-6. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23440284 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1656537
- ↑ 2.0 2.1 FDA MedWatch. August 28, 2015 DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm460238.htm
- ↑ 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ 4.0 4.1 Li L, Li S, Deng K et al Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26888822 Free Article <Internet> http://www.bmj.com/content/352/bmj.i610
- ↑ 5.0 5.1 Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017 Feb; 40:284. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27659407 <Internet> http://care.diabetesjournals.org/content/40/2/284
DeVries JH, Rosenstock J. DPP-4 inhibitor-related pancreatitis: Rare but real! Diabetes Care 2017 Feb; 40:161 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28108536 <Internet> http://care.diabetesjournals.org/content/40/2/161 - ↑ 6.0 6.1 Liu J, Li L, Deng K et al Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017 Jun 8;357:j2499. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28596247 Free PMC Article
- ↑ 7.0 7.1 7.2 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ 8.0 8.1 Abrahami D, Douros A, Yin H, et al Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 2018;360:k872 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29563098 <Internet> http://www.bmj.com/content/360/bmj.k872
- ↑ 9.0 9.1 Abrahami D, Douros A, Yin H et al Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:k4880 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30518618 https://www.bmj.com/content/363/bmj.k4880
- ↑ 10.0 10.1 10.2 Lee M et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care 2019 Nov; 42:2057 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31431452 https://care.diabetesjournals.org/content/42/11/2057
- ↑ 11.0 11.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019